IXP, a venture capital firm focused on life sciences, has launched its first investment fund to support early-stage biotech startups in India. Named the IXP Lifesciences Catalyst Fund, this fund aims to provide financial and research support to companies working in pharmaceuticals, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals.
With a total corpus of Rs 200 crore, along with an additional Rs 100 crore available through a greenshoe option, the fund will help startups at the pre-seed to Series A stages. The goal is to create a strong portfolio of 20-25 biotech startups that can drive innovation in India’s life sciences sector.
Helping Early-Stage Biotech Startups
Biotech startups often face capital-intensive and time-consuming research and development (R&D) processes before their innovations can be commercialized. IXP aims to solve these challenges by working closely with scientists and entrepreneurs to turn ideas into market-ready products.
One of its key initiatives, the IXP Venture Studio, will play an essential role in guiding biotech startups. Through this platform, IXP provides not only funding but also strategic mentorship, helping scientists transition into business leaders. The Venturepreneur Program, launched as part of the studio, is designed to train scientists who want to establish their own companies.
According to Vishal Goel, Partner at IXP and Co-founder of JV Ventures, India’s lifesciences industry has immense untapped potential. The firm’s hands-on approach ensures that biotech startups receive continuous guidance from concept to commercialization, making it different from traditional venture capital firms.
Support Beyond Capital
IXP does not just provide financial investments; it also gives biotech startups access to essential laboratory infrastructure, research networks, and R&D services. This is made possible through PoweRx, the life sciences vertical of JV Ventures, which is IXP’s principal backer.
Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures, highlighted that the success of biotech startups depends on several factors, not just funding. They require state-of-the-art laboratories, strong industry connections, and expert R&D support, which IXP provides through its network. This unique ecosystem-driven approach makes IXP different from many other investment funds.
Drive Biotech Innovation
To understand the specific needs of Indian biotech startups, IXP conducted a pan-India survey before launching its fund. The research identified several challenges faced by life sciences entrepreneurs, including access to funding, mentorship, and scientific expertise.
Dr. Ketki Tulpule, Chief Investment Officer at IXP, explained that investing in biotech requires deep scientific knowledge, industry experience, and operational expertise. The firm has brought in industry veterans as advisors and council members to guide portfolio companies. Their insights and mentorship will help startups navigate the complexities of biotech development and bring innovative products to market.
Chapter for Biotech Sector
With the launch of its Rs 200 crore biotech fund, IXP is taking a major step toward advancing India’s life sciences industry. By offering financial investments, mentorship, research support, and industry connections, the firm aims to accelerate the growth of biotech startups and drive scientific innovation.
This initiative not only strengthens India’s position in global biotechnology but also creates new opportunities for scientists, entrepreneurs, and investors in the country’s growing life sciences sector.
